Fig. 7

AGMAT inhibits SFRP2 + CAF infiltration to increase the therapeutic sensitivity to oxaliplatin. (A) Mice tumor growth curves. (B-C) Images of subcutaneous tumors in nude mice and the tumor weights (g) of the four groups. (D) HE staining and IHC staining of SFRP2 and ki-67 in subcutaneous tumors. (E) The mIHC images of indicated SFRP2 + CAF (yellow), AGMAT + cancer (red), CAFs (green) and FOXP3 + Treg (blue) in CRC samples. Quantification of fluorescence intensity (right) of SFRP2 and FOXP3. The yellow arrow indicates ACTA2 + SFRP2 + CAF, and the blue arrow indicates FOXP3 + Treg. Unpaired t-test were used to compare two groups. *p<0.05, *p<0.01, *p<0.001